West Virginia University Logo

Disease Site: Melanoma and Other Skin Cancers

6 protocol(s) meet the specified criteria

  • CA209357A US Multisite Observational Study in Patients with Unresectable and Metastatic Melanoma: the OPTIMIzE Study
  • DV3-MEL-01A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma
  • EA6134A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
  • EAY131Molecular Analysis for Therapy Choice (MATCH)
  • LOXO-TRK-15002A Phase II Basket Study of Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
  • S1404A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma